We will have to be patient because progress 'hints' on the most important trial endpoints - i.e. clinical efficacy - are unlikely before mid year or later.
Nevertheless, news flow in the first 6 months is likely to include:
1. Progress with recruitment
2. Commencement of trials at PA and Melbourne Hospitals (unless all 30 Phase 1 recruits are scheduled for Liverpool)
3. Results of Phase 1 - device validation and safety confirmation (in accordance with TGA requirements) and algorithm enhancement
4. Updated timetable for Phase 2 - specificity and sensitivity
Great time for a top-up!
Ann: EMVision Commences Clinical Trial, page-34
Add EMV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.02 |
Change
0.033(1.64%) |
Mkt cap ! $172.5M | |||
| Open | High | Low | Value | Volume |
| $1.98 | $2.02 | $1.94 | $41.93K | 21.40K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1272 | $1.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.03 | 4500 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| EMV (ASX) Chart |